TAKE THIS POLL |
|
|
- Biocompatibles International plc - Statement re Agreement with Eisai Co. Ltd. 16 May 2008 19:25 GMT
... more than nine clinical trials in Hepatocellular Carcinoma (HCC), the leading type of primary liver cancer. The results of four of these trials have now been reported in peer-reviewed publications.(1) ...
- Nexavar Significantly Extends Overall Survival in Liver Cancer by 47 percent 16 May 2008 15:13 GMT
... p-value=0.014) in patients in the Asia-Pacific region with advanced hepatocellular carcinoma (HCC), or primary liver cancer, versus those receiving placebo. Nexavar also significantly improved time to progression in these patients ...
- TAKE-A-LOOK-Clinical Oncology annual meeting 16 May 2008 12:39 GMT
... Study shows RAD001 froze kidney cancer for a year [nL15695357] > Onyx drug boosts liver cancer survival [nN15316331] > Amgen drug has little impact on brain cancer [nN08419268] > Vitamin ...
- Many to join relay in honor of friends, family 16 May 2008 11:19 GMT
... mom. Rose Binney, 67, had survived breast cancer for eight years and was beating liver cancer, but she developed a staph infection when her white blood cells were low. She ...
- Phase II Study Of IMC-A12 For Advanced Liver Cancer Opens For Patient Enrollment 16 May 2008 11:19 GMT
... IgG1 anti-insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody, in patients with advanced hepatocellular cancer (liver cancer) has opened for patient enrollment. This study is being carried out at the Memorial ...
- New Treatment For Hepatitis C: New Application For Drug Already Approved For Lowering Cholesterol 16 May 2008 10:18 GMT
... are cured, they feel dramatically better, their health care costs plummet, their risk of liver cancer drops dramatically, and if they do not have cirrhosis, they will not need a ...
- Bayer says Nexavar prolongs liver cancer patient's lives in phase III study 16 May 2008 06:59 GMT
... Bayer says Nexavar prolongs liver cancer patient's lives in phase III study FRANKFURT (Thomson Financial) - Bayer AG. said that ...
- Nexavar Significantly Improves Overall Survival by 47 Percent in Asia-Pacific Liver Cancer Study 16 May 2008 06:48 GMT
... p-value=0.014) in patients in the Asia-Pacific region with advanced hepatocellular carcinoma (HCC), or primary liver cancer versus those receiving placebo. Nexavar also significantly improved time to progression in these patients ...
- Bayer and Onyx Announce Nexavar Data Presentations at 44th American Society of Clinical Oncology Ann 16 May 2008 06:38 GMT
... ASCO will expand upon and support the proven efficacy and tolerability of Nexavar in liver cancer and advanced kidney cancer and provide new insight into the potential of Nexavar in ...
- Bayer and Onyx Announce Nexavar Data Presentations at 44th American Society of Clinical Oncology Annual Meeting 16 May 2008 06:38 GMT
... ASCO will expand upon and support the proven efficacy and tolerability of Nexavar in liver cancer and advanced kidney cancer and provide new insight into the potential of Nexavar in ...
- Statin Drug Used To Lower Cholesterol Effective For Hepatitis C Treatment, Study Shows 16 May 2008 04:52 GMT
... are cured, they feel dramatically better, their health care costs plummet, their risk of liver cancer drops dramatically, and if they do not have cirrhosis, they will not need a ...
- Researchers find new treatment for Hepatitis C 16 May 2008 04:51 GMT
... ensuing chronic hepatitis can result later in cirrhosis (fibrotic scarring of the liver) and liver cancer. In a study of 31 veterans at the Veterans Administration Medical Center in Oklahoma ...
- A closer look at Hepatitis B 16 May 2008 02:15 GMT
... get things ready," said Pon. His doctor diagnosed him with Hepatitis B and advanced liver cancer, and told him he had just six months to live. "We call chronic Hepatitis ...
- Onyx drug boosts liver cancer survival 16 May 2008 01:15 GMT
... by more than 47 percent during a clinical trial of Asian patients with advanced liver cancer, the company said on Thursday. Results from the 226-patient trial, released by the American ...
- Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive 15 May 2008 21:55 GMT
... States and 200 million people worldwide. It is the leading cause of cirrhosis and liver cancer, and the number one reason for liver transplants in the United States. Clinical investigators ...
- Cholesterol drug may help hepatitis C 15 May 2008 21:31 GMT
... patients are cured, they feel dramatically better, their healthcare costs plummet, their risk of liver cancer drops dramatically, and if they do not have cirrhosis, they will not need a ...
- Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting 15 May 2008 20:58 GMT
... States and 200 million people worldwide. It is the leading cause of cirrhosis and liver cancer, and the number one reason for liver transplants in the United States. Clinical investigators ...
- Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) A 15 May 2008 20:58 GMT
... States and 200 million people worldwide. It is the leading cause of cirrhosis and liver cancer, and the number one reason for liver transplants in the United States. Clinical investigators ...
- Cholesterol drug may help hepatitis C 15 May 2008 20:57 GMT
... patients are cured, they feel dramatically better, their healthcare costs plummet, their risk of liver cancer drops dramatically, and if they do not have cirrhosis, they will not need a ...
- Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) A 15 May 2008 20:57 GMT
... States and 200 million people worldwide. It is the leading cause of cirrhosis and liver cancer, and the number one reason for liver transplants in the United States. Clinical investigators ...
1 - 25 of 191 next >
News by PR Newswire
|
